Navigation Links
Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey
Date:12/23/2009

EXTON, Pa., Dec. 23 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the final wave of LaunchTrends®: Simponi and Cimzia report. The survey was completed by U.S. Rheumatologists (n=77) in late November 2009. BioTrends also conducted qualitative interviews with a subset (n=20) of the survey respondents to get an in-depth view of the sales and marketing messages being employed to differentiate the products. Over the course of the six month study over 300 Rheumatologists were interviewed about their reception to these new agents.

Awareness of both new TNF antagonists was nearly universal among the respondents. The initial favorability rating noted in baseline research in May 2009 for Centocor's Simponi decreased during subsequent waves of research and now trails UCB's Cimzia in both favorability and interest in learning more about these newest agents. The initial favorability rating for Cimzia has risen from the 31% reported in the two prior waves to 48% in this final wave of research coupled with a significant increase in familiarity with the product as well.

Cimzia has made significant gains, with new product share now split between these once-monthly products. Consistent with prior waves of research, Rheumatologists indicate that over 40% of their current patients on these newest TNF agents were switched from the current market share leaders Enbrel and Humira. Although the surveyed Rheumatologists perceive Simponi and Cimzia to be extremely similar, there have been a few areas of differentiation that have started to emerge.

Among Rheumatologists who have used the new anti-TNF products, overall satisfaction has increased to 60% with Simponi and 50% with Cimzia. While both Simponi and Cimzia are expected to gain market share in the next six months, the combined share of the two agents is not expected to exceed 12% of the biologic share in Rheumatoid Arthriti
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
3. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
4. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
5. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
6. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
7. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
8. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
9. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
10. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
11. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... HILL, N.C. , Jan. 23, 2015 For the ... are in dealing with payers. Likewise, the importance of the ... - will only continue to grow as payer formularies and ... access therapies. At the same time, managed markets ...
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... "Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends ... Video communication has been the topic of fascination ... the United States and the Soviet Russia. Earlier ...
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... the "Urinary Catheters Market (Indwelling or Foley Catheters, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... , At present, the global market for ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... Data Show Bifeprunox Maintained Stability,Significantly Longer than ... Profile Comparable with Placebo , MARIETTA, Ga. ... Solvay,Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of ... results on,bifeprunox, an investigational treatment for adult ...
... 2007 /PRNewswire-FirstCall/ -- Forest,Laboratories, Inc. and Cypress ... from a 1,196 patient randomized,three month, double-blind, ... therapeutic effects of,milnacipran as a treatment of ... only been able to review initial top-line,results ...
Cached Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6
(Date:1/22/2015)... (PRWEB) January 22, 2015 Woodloch Pines, an ... has been selected by TripAdvisor as the number one best ... 6th best in the world for their annual Travelers’ Choice ... travel community . The website is home to millions of ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... number one in the nation in cardiology and GI ... for 2008, BOSTON, May 29 Children,s Hospital ... pediatric hospitals in the country,according to U.S.News & World ... Since the magazine began ranking hospitals 19 years ago, ...
... 5; Cancer program ... in Top 10 ... Bay Area, STANFORD, Calif., May 29 Once again, Lucile Packard,Children,s Hospital ... annual America,s Best Children,s Hospitals issue hitting,newsstands June 2, the magazine places Lucile ...
... to 66% increased risk of disease after operation , , ... anti-rejection drug sirolimus may lead to increased risk of ... data on about 20,000 Medicare patients who had kidney ... patients had diabetes before their kidney transplant. Compared to ...
... Sales Managers and executives,often face questions such as: ... middle-ranking performers, Inducements have to stand out to,engender ... is a summary of a research,presentation that evaluates ... and intangible rewards used in sales recognition programs. ...
... 1 or type 2 diabetes who self-monitor their blood ... adjust treatment regimens can achieve improved glucose control, according ... Special Supplement to the June 2008 issue (Volume 10, ... journal published by Mary Ann Liebert, Inc. ( www.liebertpub.com ...
... May 29 Martek Biosciences,Corporation (Nasdaq: MATK ) ... Annual Needham & Company Biotechnology and Medical Technology,Conference in ... - 12, 2008 at,the New York Palace Hotel. Peter ... 12, 2008 at 1:30 p.m. Eastern Time., A ...
Cached Medicine News:Health News:Children's Hospital Boston Ranked Number One in New England 2Health News:Children's Hospital Boston Ranked Number One in New England 3Health News:U.S.News 2008 'Best Hospitals' Issue Again Ranks Packard Children's as One of Nation's Best 2Health News:Anti-Rejection Drug May Boost Diabetes in Kidney Transplant Patients 2Health News:Best Practices in Sales Recognition 2Health News:Special supplement on self-monitoring of blood glucose in diabetes technology & therapeutics 2
... blood oximeters provide cardiologists with critical ... a patient's blood. The Oxicom series ... over a half-million saturation samples measured ... cost-effective oxygen saturation readings in less ...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
Medicine Products: